← Leaderboards
Kevin Wendell Bruhn
Novadigm Therapeutics, Inc.
$298,561
Attributed
$298,561
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$298,561 · 1
By mechanism
R43$298,561 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “S Adjuvant”
- Lawrence Corey · Fred Hutchinson Cancer Center$377,142,999
- Norman Wolmark · Nsabp Foundation, Inc.$267,141,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$167,183,168
- David Heimbrook · Leidos Biomedical Research, Inc.$151,668,128
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$131,206,481
- Peter B. Gilbert · Fred Hutchinson Cancer Center$117,668,001
Research focus
S AdjuvantAdhesionsBacterial VaccinesAla1 Protein, Candida AlbicansAmotosalenAnimal ModelAntifungal AgentsAntifungal TherapyAntigen PresentationAntigensAntigens, HeterophileAttenuatedAttributable MortalityBacteriaAdjuvantBaseBloodCandidaCandidiasisCd8b1 GeneCell Mediated Immune ResponseCellsCharacteristicsAdhesins, Bacterial